Consequently, downregulation of the PI3K-Akt/NF-κB/mTOR, STAT3, and CDK6 signaling pathways was reportedly used to abrogate GBM oncogenic properties and re-sensitized aggressive glioblastomas to chemotherapy [75,76,77]. The gene discussed is AKT1; the disease is glioblastoma.